Business Wire

KOLMAR-BNH

28.5.2024 15:01:28 CEST | Business Wire | Press release

Share
Kolmar BNH Expands Its Global Market by Launching HemoHIM G in Taiwan

Kolmar BNH (KRX: 200130), a prominent Korean health functional food Original Development Manufacturing (ODM) firm, announced that it has unveiled its latest offering, HemoHIM G, in Taiwan. This introduction is part of the company's endeavor to expand its presence in global markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527924165/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Manufactured by Kolmar BNH and distributed by Atomy, HemoHIM G, containing Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora, is now available in Taiwan. (Photo: Kolmar BNH)

HemoHIM G represents an enhanced iteration of HemoHIM, tailored to meet the distinctive tastes of consumers in Taiwan and Europe.

Kolmar BNH plans to expedite its market expansion in Asia by launching HemoHIM G in the Taiwan market on May 15. HemoHIM G, tailored for international export, has made meticulous adjustments in raw materials and ingredient proportions to comply with varying food regulations across different jurisdictions. Key ingredients such as Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora went through rigorous sourcing procedures, accompanied by stringent quality control measures. The taste and aroma profiles were tailored to suit the preferences of European consumers.

Furthermore, in April, Kolmar BNH's research findings on HemoHIM G were published in the esteemed academic journal 'Toxicological Research,' accredited at the SCIE level. These findings, which adhere to OECD guidelines, hold paramount significance as they not only validate the product's safety for regulatory compliance in diverse markets but also bolster intellectual property rights through reliable results.

HemoHIM, Kolmar BNH's flagship product, is distributed through its partner Atomy. The product has achieved remarkable milestones, surpassing KRW 2 trillion in cumulative sales at home and abroad since its launch. The product's success is attributed to Kolmar BNH's research and development capabilities, coupled with enduring consumer trust built over time.

The product name HemoHIM derives from the fusion of ‘HEMO (hemoglobin)’ and ‘HIM (H: hematopoiesis, I: immunity, and M: modulation)’. It encompasses extracts sourced from natural medicinal herbs such as Angelica gigas, Cnidium officinale, and Paeonia japonica. This accomplishment is a result of the collaborative endeavors of Kolmar BNH, established jointly by the Korea Atomic Energy Research Institute and Kolmar Korea, with a budget of KRW 5 billion over eight years.

Notably, the Korea Atomic Energy Research Institute, an institution concerned with radiation, has reinforced trust in HemoHIM, as it initiated research for self-protection purposes. This collaboration, combined with Kolmar BNH's expertise in commercialization and production technology, culminated in the successful development of a blended substance that enhances immune function.

HemoHIM gained recognition from the Ministry of Food and Drug Safety in 2006 as the first individually recognized functional raw material in Korea for enhancing immune function. It marked a pioneering milestone in functional food development within Korea, particularly at a juncture when research and raw materials for improving immune function were scarce.

Kolmar BNH has been reinforcing reliability through sustained research and development endeavors since the launch of HemoHIM. Consistently allocating more than 2% of its annual sales to R&D initiatives for new developments, the company achieved a significant milestone by integrating fatigue improvement functionality into HemoHIM. This came six years after the 'HemoHIM sustainable technology development project' began in 2017.

Kolmar BNH has grown by leaps and bounds with HemoHIM. In 2015, when it was listed on Korea’s key stock market KOSDAQ, the company posted sales of KRW 236.2 billion, and last year it surged 145% to KRW 579.6 billion.

An official from Kolmar BNH said, "The enduring appeal of HemoHIM among consumers underscores its proven functionality. We will remain steadfast in our commitment to advancing research and development efforts to uphold HemoHIM's status as Korea's premier functional health food."

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240527924165/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release

Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release

Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release

ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release

Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release

Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye